


# Clinical response of patients with advanced Renal Carcinoma treated with Small Proteolytic particle immunomodulatory


IUC20757-86

CABALLERO-AGUIRRECHU I, MESA C, ÁLVAREZ R, OLIVER L, GÓMEZ D, RODRÍGUEZ R, ROSALES A, VEGA G.  
HOSPITAL HERMANOS AMEIJERAS, LA HABANA. CENTRO DE INMUNOLOGÍA MOLECULAR, LA HABANA, CUBA


- **Advanced RCC-** high immunogenicity (GM3) and resistance to systemic chemotherapy. Its “Molecular Targets” time.
- **VSSP** in experimental studies of RCC inhibits the suppressive function of MDSC (G-CSF) and induces differentiation to DC and MDSC.
- **Primary objectives:** kinetics of peripheral concentrations myeloid-derived suppressor cells (MDSC) and survival/safety VSSP vaccine.
- **Study design:** descriptive and longitudinal, cross-sectional study with 30 metastatic’s RCC patients treated with natural **N**Acetyl **GM3/VSSP**.



## Kinetics of MDSC serological concentrations in advanced RCC patients



## Survival by Risk Group in advanced RCC. (n=30)



## TAKE HOME

- Young patient’s CRC with lung metastases, intermediate risk group and right kidney predominated.
- High concentrations of Myeloid-derived Suppressor Cells (MDSC) at inclusion and their decrease with VSSP vaccine.
- Survival rates with VSSP vaccine correspond to those reported with other immunotherapy drugs in advance RCC patients. Administration was safe (No AEs).